153 related articles for article (PubMed ID: 29093271)
1. Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Mirza AN; Fry MA; Urman NM; Atwood SX; Roffey J; Ott GR; Chen B; Lee A; Brown AS; Aasi SZ; Hollmig T; Ator MA; Dorsey BD; Ruggeri BR; Zificsak CA; Sirota M; Tang JY; Butte A; Epstein E; Sarin KY; Oro AE
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093271
[TBL] [Abstract][Full Text] [Related]
2. GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas.
Atwood SX; Li M; Lee A; Tang JY; Oro AE
Nature; 2013 Feb; 494(7438):484-8. PubMed ID: 23446420
[TBL] [Abstract][Full Text] [Related]
3. MTOR promotes basal cell carcinoma growth through atypical PKC.
Chow RY; Levee TM; Kaur G; Cedeno DP; Doan LT; Atwood SX
Exp Dermatol; 2021 Mar; 30(3):358-366. PubMed ID: 33617094
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.
Coni S; Mancuso AB; Di Magno L; Sdruscia G; Manni S; Serrao SM; Rotili D; Spiombi E; Bufalieri F; Petroni M; Kusio-Kobialka M; De Smaele E; Ferretti E; Capalbo C; Mai A; Niewiadomski P; Screpanti I; Di Marcotullio L; Canettieri G
Sci Rep; 2017 Mar; 7():44079. PubMed ID: 28276480
[TBL] [Abstract][Full Text] [Related]
5. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
[TBL] [Abstract][Full Text] [Related]
6. LAP2 Proteins Chaperone GLI1 Movement between the Lamina and Chromatin to Regulate Transcription.
Mirza AN; McKellar SA; Urman NM; Brown AS; Hollmig T; Aasi SZ; Oro AE
Cell; 2019 Jan; 176(1-2):198-212.e15. PubMed ID: 30503211
[TBL] [Abstract][Full Text] [Related]
7. Loss of protein kinase Calpha expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma.
Neill GW; Ghali LR; Green JL; Ikram MS; Philpott MP; Quinn AG
Cancer Res; 2003 Aug; 63(15):4692-7. PubMed ID: 12907651
[TBL] [Abstract][Full Text] [Related]
8. Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas.
Whitson RJ; Lee A; Urman NM; Mirza A; Yao CY; Brown AS; Li JR; Shankar G; Fry MA; Atwood SX; Lee EY; Hollmig ST; Aasi SZ; Sarin KY; Scott MP; Epstein EH; Tang JY; Oro AE
Nat Med; 2018 Mar; 24(3):271-281. PubMed ID: 29400712
[TBL] [Abstract][Full Text] [Related]
9. Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma.
Ning H; Mitsui H; Wang CQ; Suárez-Fariñas M; Gonzalez J; Shah KR; Chen J; Coats I; Felsen D; Carucci JA; Krueger JG
Oncotarget; 2013 Dec; 4(12):2237-48. PubMed ID: 24163262
[TBL] [Abstract][Full Text] [Related]
10. Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Ally MS; Ransohoff K; Sarin K; Atwood SX; Rezaee M; Bailey-Healy I; Kim J; Beachy PA; Chang AL; Oro A; Tang JY; Colevas AD
JAMA Dermatol; 2016 Apr; 152(4):452-6. PubMed ID: 26765315
[TBL] [Abstract][Full Text] [Related]
11. Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity.
Grund-Gröschke S; Ortner D; Szenes-Nagy AB; Zaborsky N; Weiss R; Neureiter D; Wipplinger M; Risch A; Hammerl P; Greil R; Sibilia M; Gratz IK; Stoitzner P; Aberger F
Mol Oncol; 2020 Sep; 14(9):1930-1946. PubMed ID: 32615027
[TBL] [Abstract][Full Text] [Related]
12. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
[TBL] [Abstract][Full Text] [Related]
13. HDAC1/2 Control Proliferation and Survival in Adult Epidermis and Pre‒Basal Cell Carcinoma through p16 and p53.
Zhu X; Leboeuf M; Liu F; Grachtchouk M; Seykora JT; Morrisey EE; Dlugosz AA; Millar SE
J Invest Dermatol; 2022 Jan; 142(1):77-87.e10. PubMed ID: 34284046
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin.
Makinodan E; Marneros AG
Exp Dermatol; 2012 Nov; 21(11):847-52. PubMed ID: 23163650
[TBL] [Abstract][Full Text] [Related]
15. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
[TBL] [Abstract][Full Text] [Related]
16. YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
Dong S; Ma X; Wang Z; Han B; Zou H; Wu Z; Zang Y; Zhuang L
Oncotarget; 2017 Jun; 8(25):40583-40593. PubMed ID: 28489564
[TBL] [Abstract][Full Text] [Related]
17. Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth.
Ruan H; Luo H; Wang J; Ji X; Zhang Z; Wu J; Zhang X; Wu X
Biochim Biophys Acta; 2016 Sep; 1860(9):1961-72. PubMed ID: 27316313
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Li S; Chen X; Mao L; Zahid KR; Wen J; Zhang L; Zhang M; Duan J; Duan J; Yin X; Wang Y; Zhao L; Tang X; Wang X; Xu G
Brain Res; 2018 Aug; 1692():154-162. PubMed ID: 29782850
[TBL] [Abstract][Full Text] [Related]
19. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.
Kim DJ; Kim J; Spaunhurst K; Montoya J; Khodosh R; Chandra K; Fu T; Gilliam A; Molgo M; Beachy PA; Tang JY
J Clin Oncol; 2014 Mar; 32(8):745-51. PubMed ID: 24493717
[TBL] [Abstract][Full Text] [Related]
20. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
